Subscribe to RSS
DOI: 10.1055/s-0038-1640119
Hearing after induction chemotherapy and definitive chemoradiotherapy in advanced oropharyngeal carcinoma
In patients with locally advanced oropharyngeal carcinoma, neoadjuvant induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) with subsequent definitive chemoradiotherapy is an established and regularly used treatment option. For cisplatin, a partially dose-dependent, non-reversible ototoxicity with complex molecular and cellular mechanisms is known. The aim of this study is to test in a pilot study whether and to what extent a hearing loss occurs in oropharyngeal carcinoma in connection with the therapy mentioned above.
In a retrospective study, the pure tone audiograms (0.125 – 8 kHz) of 14 patients with oropharyngeal carcinoma before and after cisplatin-based induction chemotherapy were evaluated with subsequent definitive radiochemotherapy. In 9 of the 14 patients, hearing decreased by 10 dB or more in at least one frequency on at least one side. A conductive hearing loss as a result of a tympanic effusion occurred in one case.
Intensive multimodal forms of therapy using cisplatin are accompanied by regularly occurring ototoxicity, which should be given more prominence in clinical practice and in the pretreatment patient information.
Publication History
Publication Date:
18 April 2018 (online)
© 2018. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Stuttgart · New York